These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 15769894)

  • 1. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction.
    Adam C; King S; Allgeier T; Braumüller H; Lüking C; Mysliwietz J; Kriegeskorte A; Busch DH; Röcken M; Mocikat R
    Blood; 2005 Jul; 106(1):338-44. PubMed ID: 15769894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.
    Hömberg N; Adam C; Riedel T; Brenner C; Flatley A; Röcken M; Mocikat R
    Int J Cancer; 2014 Dec; 135(12):2825-33. PubMed ID: 24771135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell-induced activation of adaptive and innate antitumor immunity.
    van den Broeke LT; Daschbach E; Thomas EK; Andringa G; Berzofsky JA
    J Immunol; 2003 Dec; 171(11):5842-52. PubMed ID: 14634094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency.
    Umeshappa CS; Nanjundappa RH; Xie Y; Freywald A; Xu Q; Xiang J
    Immunology; 2013 Apr; 138(4):298-306. PubMed ID: 23113741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction.
    Kim KD; Choi SC; Kim A; Choe YK; Choe IS; Lim JS
    Int Immunopharmacol; 2001 Nov; 1(12):2117-29. PubMed ID: 11710541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8
    Yu Z; Liu W; He Y; Sun M; Yu J; Jiao X; Han Q; Tang H; Zhang B; Xian Y; Qi J; Gong J; Xin W; Shi G; Shan F; Zhang R; Li J; Wei M
    J Hematol Oncol; 2021 Apr; 14(1):71. PubMed ID: 33910591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
    Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
    Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
    Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
    Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.
    Stober D; Jomantaite I; Schirmbeck R; Reimann J
    J Immunol; 2003 Mar; 170(5):2540-8. PubMed ID: 12594280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged antitumor NK cell reactivity elicited by CXCL10-expressing dendritic cells licensed by CD40L+ CD4+ memory T cells.
    Shimizu K; Asakura M; Fujii S
    J Immunol; 2011 May; 186(10):5927-37. PubMed ID: 21460206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
    Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
    Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor.
    Zhou H; Luo Y; Kaplan CD; Krüger JA; Lee SH; Xiang R; Reisfeld RA
    Blood; 2006 Apr; 107(8):3251-7. PubMed ID: 16368879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells.
    Karimi K; Boudreau JE; Fraser K; Liu H; Delanghe J; Gauldie J; Xing Z; Bramson JL; Wan Y
    Mol Ther; 2008 Feb; 16(2):411-8. PubMed ID: 18059374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway.
    Westwood JA; Kelly JM; Tanner JE; Kershaw MH; Smyth MJ; Hayakawa Y
    J Immunol; 2004 Jan; 172(2):757-61. PubMed ID: 14707044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function.
    Mailliard RB; Son YI; Redlinger R; Coates PT; Giermasz A; Morel PA; Storkus WJ; Kalinski P
    J Immunol; 2003 Sep; 171(5):2366-73. PubMed ID: 12928383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
    Hu HM; Winter H; Urba WJ; Fox BA
    J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination.
    van Beek JJ; Wimmers F; Hato SV; de Vries IJ; Sköld AE
    Crit Rev Immunol; 2014; 34(6):517-36. PubMed ID: 25597314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic T-cell response induced by tumor delivery of TNF and melphalan is dependent on early triggering of natural killer and dendritic cells.
    Balza E; Zanellato S; Poggi A; Reverberi D; Rubartelli A; Mortara L
    Eur J Immunol; 2017 Apr; 47(4):743-753. PubMed ID: 28198545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.